Join the Working Group on New TB Vaccines

The WGNV is an informal network of stakeholders engaged in all aspects of TB vaccine R&D, including TB vaccine advocacy, and from all constituencies, including academics, product developers, clinicians, advocates, funders, policymakers, and affected communities. The WGNV helps to facilitate the development of new, more effective TB vaccines by promoting consensus, scientific exchange, and advocacy in support of TB R&D. Members will be kept informed of new developments in TB vaccine research and opportunities to engage in efforts to advance TB vaccine R&D, including current TB vaccine advocacy activities. Current advocacy activities include those coordinated by the TB Vaccine Advocacy Roadmap (TB Vax ARM) – a global coalition of TB stakeholders, including TB survivors, civil society organizations, and scientific non-profits.

Are you involved in or planning an advocacy initiative to support TB vaccine R&D? Contact us!

TB Vaccine Advocacy Social Media Fellowship

At the beginning of February 2022, IAVI will officially launch a social media fellowship as part of the TB Vax ARM efforts. The fellowship will convene three TB vaccine R&D advocates representing TB affected communities and early career researchers for a social media skill building and campaign development program.

Starting during the first week of February, the fellowship will engage advocates in a 15 hour program over the course of six weeks, ending in the second week of March. In collaboration with the IAVI communications team, the fellows will develop and run a social media-based TB vaccine R&D advocacy campaign in the lead up to the 6th Global Forum on TB Vaccines, taking place between 22-25 February 2022.

Click the button below to learn more.

Applications are now closed.

If you have any questions about this initiative or other opportunities with the TB Vax ARM, email Shaun Palmer at spalmer@iavi.org.

Open Letter to G20 Health & Finance Ministers

Led by a group of TB survivors and advocates, and coordinated by the TB Vax ARM, an open letter was sent to G20 Health and Finance Ministers ahead of their joint meeting on October 29, 2021. The letter called our leaders to uphold global commitments to end TB by 2030 by ensuring an annual investment of USD $1 billion to close the funding gap and make new TB vaccines possible as early as 2025.

Signed by survivors from all G20 nations and supported by 58 allied organisations, the campaign's impact was felt around the world, reaching over 880,000 screens on social media and featuring in an article in the Guardian Global Development.

Does your organisation want to support future calls to action or would you like to offer your personal support as a country representative? Then email Shaun Palmer at spalmer@iavi.org.